Valuation: Natera, Inc.

Market Cap 46.27B 41.93B 38.78B 34.99B 65.94B 4,363B 68.27B 466B 185B 2,330B 174B 170B 7,398B P/E 2026 *
-205x
P/E 2027 * -803x
Enterprise Value 45.22B 40.98B 37.91B 34.2B 64.45B 4,264B 66.72B 455B 181B 2,278B 170B 166B 7,230B EV / Sales 2026 *
15x
EV / Sales 2027 * 12.3x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day-1.19%
1 week+2.71%
Current month-22.98%
1 month-21.17%
3 months+2.96%
6 months+71.22%
Current year+39.29%
1 week 304.65
Extreme 304.65
326.92
1 month 304
Extreme 304
436.19
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 53.06
Extreme 53.0601
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 43 05/11/2026
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 43 05/11/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Chief Financial Officer

-470 0.0003%
02/11/26 Sell

Founder

-341 0.0002%
02/11/26 Sell

Chief Executive Officer

-3,419 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%+2.71%+56.20%+502.40% 46.27B
-0.49%+6.56%+14.83%+29.25% 114B
-0.32%+0.82%+5.59%+107.01% 104B
+0.62%+2.17%+10.06%+99.63% 33.33B
-0.49%+1.07%+38.81%+76.49% 30.08B
-0.02%+1.55%+38.86%+91.66% 28.56B
-0.29%+0.95%+48.27%+387.69% 22.76B
-0.70%-1.35%-18.92%-19.66% 19.92B
+0.50%+2.97%-2.80%+33.28% 17.15B
-0.34%+6.05%+122.53% - 14.84B
Average -0.27%+2.39%+31.34%+145.30% 43B
Weighted average by Cap. -0.36%+2.90%+23.14%+131.98%

Financials

2026 *2027 *
Net sales 3.01B 2.73B 2.53B 2.28B 4.29B 284B 4.45B 30.34B 12.03B 152B 11.31B 11.07B 482B 3.65B 3.31B 3.06B 2.76B 5.21B 345B 5.39B 36.8B 14.59B 184B 13.72B 13.43B 584B
Net income -227M -206M -191M -172M -324M -21.43B -335M -2.29B -908M -11.45B -853M -835M -36.34B -51.83M -46.97M -43.44M -39.2M -73.87M -4.89B -76.47M -522M -207M -2.61B -195M -190M -8.29B
Net Debt -1.05B -948M -876M -791M -1.49B -98.59B -1.54B -10.53B -4.17B -52.66B -3.92B -3.84B -167B -1.36B -1.23B -1.14B -1.03B -1.94B -128B -2.01B -13.69B -5.43B -68.47B -5.1B -4.99B -217B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
13/11/26 $319.09 -1.19% 1,690,805
12/11/26 $322.94 +0.98% 1,500,784
11/11/26 $319.82 +2.51% 1,746,887
10/11/26 $311.98 -2.62% 1,751,255
09/11/26 $320.39 +3.13% 2,784,479
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
319.09USD
Average target price
410.26USD
Spread / Average Target
+28.57%
  1. Stock Market
  2. Stocks
  3. NTRA Stock